Early study drug for advanced cancers after other treatments
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests AMT-116, an investigational medicine, in people with advanced solid cancers that can’t be removed by surgery and have gotten worse after standard treatment. It looks for the best safe dose and early signs the treatment may shrink tumors or slow growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent and follow the visit schedule
- Have an advanced solid tumor that cannot be removed with surgery, confirmed by biopsy/pathology
- Have tried at least one cancer treatment and your cancer has grown or you couldn’t tolerate standard options
- Have at least one measurable tumor spot doctors can track on scans (measurable lesion)
- Have good day-to-day function (ECOG performance status 0–1)
- Have a tumor tissue sample available for testing (old sample or a new biopsy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests AMT-253, an experimental drug, in people with advanced solid cancers that have grown despite prior treatment (or where standard options were not tolerated). The goal is to find a safe dose and learn how the drug affects the cancer.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This Phase 1/2 trial tests MHB036C in people with advanced or metastatic solid cancers that have stopped responding to standard treatments (or no standard options exist). It is meant to see how the drug works and how safe it is in this group.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This Phase 1 trial tests an early, first-in-people treatment (XT-0528) for people with advanced solid cancers that cannot be removed or have spread. The goal is to check safety and find out what doses might work, and it may help you if standard options are no longer available.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.